RecruitingPhase 1Phase 2NCT06499350

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

A Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of AXL Inhibitor FC084CSA Tablets in Combination With Tislelizumab in the Treatment of Advanced Malignant Solid Tumors

Sponsor

FindCure Biosciences (ZhongShan) Co., Ltd.

Enrollment

33 participants

Start Date

Nov 13, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced malignant solid tumors

Summary

The goal of this clinical trial is to learn the safety, tolerability, pharmacokinetic characteristics and efficacy of FC084CSA in combination with Tislelizumab in patients with advanced malignant solid tumors.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called FC084CSA+Tislelizumab combination (dose escalation) and a drug called RP2D of FC084CSA+Tislelizumab combination (dose expansion) for people with advanced malignant solid tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.